Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Earnings Data
Report Date
Mar 02, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.14Last Year’s EPS
0.86Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with robust revenue growth and strategic investments in DAYBUE and NUPLAZID, alongside pipeline advancements. However, challenges persist with DAYBUE's market penetration and increased R&D expenses.Company Guidance
Strong Revenue Growth
Total revenues for Q3 2025 were $278.6 million, up 11% year-over-year, with DAYBUE and NUPLAZID showing significant sales growth.
DAYBUE Sales Milestone
DAYBUE achieved net sales of $101.1 million in Q3, marking the highest revenue and total prescription volume since launch.
NUPLAZID Record Performance
NUPLAZID delivered net sales of $177.5 million in Q3, representing a 12% year-over-year growth and a 9% increase in volume.
Pipeline Advancements
Initiation of Phase II study for ACP-204 in Lewy body dementia psychosis and Phase III study of trofinetide in Japan, with additional studies planned for the coming years.
Cash Position
The company ended the quarter with $847 million in cash, up from $762 million at the end of the second quarter.
ACAD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACAD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $22.33 | $21.65 | -3.05% |
Aug 06, 2025 | $23.80 | $24.40 | +2.52% |
May 07, 2025 | $14.81 | $16.93 | +14.31% |
Feb 26, 2025 | $19.00 | $19.34 | +1.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ACADIA Pharmaceuticals (ACAD) report earnings?
ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Mar 02, 2026, After Close (Confirmed).
What is ACADIA Pharmaceuticals (ACAD) earnings time?
ACADIA Pharmaceuticals (ACAD) earnings time is at Mar 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACAD EPS forecast?
ACAD EPS forecast for the fiscal quarter 2025 (Q4) is 0.14.